Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Chinese Medicine
Published in: Chinese Medicine 1/2018

Open Access 01-12-2018 | Review

Psoriasis therapy by Chinese medicine and modern agents

Authors: Shikang Meng, Zibei Lin, Yan Wang, Zhenping Wang, Ping Li, Ying Zheng

Published in: Chinese Medicine | Issue 1/2018

Login to get access

Abstract

Psoriasis is a chronic, painful, disfiguring and non-contagious skin disease that has globally affected at least 200 million patients. In general, mild to moderate psoriasis patients will be treated by chemical drugs or Chinese medicine, while targeting systemic biological drugs have been successfully developed with good efficacy but high cost burden to patients with severe psoriasis. Since the underlying mechanisms of psoriasis are not well understood, in this review, psoriasis pathogenesis and clinical therapeutic principles by modern medicine and Chinese medicine are extensively described. Based on the data from the China Food and Drug Administration, the majority of chemical drugs are utilized as the topical formulations, while Chinese medicines are mainly delivered by an oral route, suggesting that the market for topical preparations of Chinese medicine to treat psoriasis is worth to exploration. Moreover, considering the unique clinical therapeutic theory and successful clinical application of Chinese medicine in the treatment of psoriasis, we believe that development of new small molecule drugs based on Chinese medicine will be a promising strategy to reduce therapeutic costs and improve safety for psoriatic patients.
Literature
1.
2.
Organization WH. Global report on psoriasis. 2016. WHO Library Cataloguing-in-Publication Data 2016.
3.
Xiao-lan D, Ting-lin W, Yi-wei S, Xiao-yan W, Cheng Z, Shan T, Ying L, Guang-hui P, Jun-e A, Shu-qi X. Prevalence of psoriasis in China: an epidemiological survey in six Provinces. Chin J Derm Venerol. 2010;24(7):598–601.
4.
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–6.CrossRefPubMed
5.
Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–9.CrossRefPubMed
6.
Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–73.CrossRefPubMed
7.
8.
Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1(5):442–7.CrossRefPubMed
9.
10.
11.
Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467–76.CrossRefPubMed
12.
Zhao JX, Wang Y, Di TT, Liu X, Li P. The IL-23/IL-17 axis in the immunopathogenesis of psoriasis. Basic Clin Med. 2012;4:027.
13.
Dolgin E. New anti-IL-23 drugs raise hopes for psoriasis plaque clearance. London: Nature Publishing Group; 2016.
14.
McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23–IL-17 immune pathway. Trends Immunol. 2006;27(1):17–23.CrossRefPubMed
15.
Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, Everitt DE, Frederick B, Zhu Y, Graham MA. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Investig Dermatol. 2004;123(6):1037–44.CrossRefPubMed
16.
van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus A-M, Florencia E, Prens EP. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182(9):5836–45.CrossRefPubMed
17.
Lillis JV, Guo C-S, Lee JJ, Blauvelt A. Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis. Arch Dermatol. 2010;146(8):918–35.CrossRefPubMed
18.
Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, Blauvelt A. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Investig Dermatol. 2009;129(9):2175–83.CrossRefPubMedPubMedCentral
19.
Woo YR, Cho DH, Park HJ. Molecular mechanisms and management of a cutaneous inflammatory disorder: psoriasis. Int J Mol Sci. 2017;18(12):2684.CrossRefPubMedCentral
20.
Kim J, Krueger JG: Psoriasis and other skin inflammatory diseases. Inflammation: from molecular and cellular mechanisms to the clinic; 2018. p. 1091–1104.
21.
22.
23.
Rizvi S, Chaudhari K, Syed BA. The psoriasis drugs market. Nat Rev Drug Discovery. 2015;14(11):745–6.CrossRefPubMed
24.
branch CSoDP. Chinese psoriasis treatment experts consensus (2014 Edition). Chin J Dermatol. 2014;47(3):3.
25.
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths C, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.CrossRefPubMed
26.
Griffiths G, Clark C, Chalmers R, Li Wan Po A, Williams H. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000;4:1–125.CrossRefPubMed
27.
Colao R, Yanofsky VR, Lebwohl MG. Successful treatment of palmoplantar psoriasis using combination acitretin and apremilast: a case report. J Psoriasis Psoriatic Arthritis. 2016;1(2):66–9.CrossRef
28.
AbuHilal Md, Walsh S, Shear N. Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study. J Cutan Med Surg. 2016;20(4):313–6.CrossRefPubMed
29.
Lapteva M, Mondon K, Möller M, Gurny R, Kalia YN. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. Mol Pharm. 2014;11(9):2989–3001.CrossRefPubMed
30.
Chao Y. General treatise on the cause and symptoms of diseases. Beijing: People’s Medical Publishing House; 1955.
31.
Wu Q. The golden mirror of medicine. Beijing: People’s Medical Publishing House; 1973.
32.
Zhao B. Zhao Bingnan clinical experience set. Beijing: People’s Medical Publishing House; 1975.
33.
Bingnan Zhao ZZ. Concise dermatology of traditional Chinese medicine. Beijing: China outlook press; 1983.
34.
Song P, Li B. Sharing the methods of “Treated form blood differentiation”—experiences of Renkang Zhu in treating psoriasis. Chin J Tradit Chin west Med. 2004;01:1–2.
35.
Qifeng Jin DZ. Dermatology of TCM. Beijing: Beijing China Medical Science and Technology Press; 2001.
36.
Wang P, Zhang P, Deng B, Sun L. TCM syndrome differentiation and psoriasis treatment of Zhili Zhang. Chin J Tradit Chin West Med. 2004;04:191–3.
37.
Xu Y. Dermatology TCM diagnosis and treatment. Beijing: People’s Medical Publishing House; 1997.
38.
Ma S, Li Y. Report of 312 cases of psoriasis treated by syndrome differentiation. Hunan Guiding J TCMP. 1999;07:21.
39.
Bingxu DC, Chunyan J, Ping W. The rule of distribution and development of TCM syndromes of psoriasis. J Tradit Chin Med. 2006;47:770–2.
40.
Li J, Xu L, Zhou F, Jiang Y, Zhang T, Li D, Zheng D. Study on the distribution of TCM syndrome of psoriasis in central China. Chin J Tradit Chin West Med. 2011;01:8–12.
41.
Zhang G, Wang P, Wang J, Jiang C, Deng B, Li P, Zhang Y, Liu W, Qu X, Chen W, et al. The distribution of syndrome manifestations and evolvement rules on 2651 psoriasis vulgaris cases. J Tradit Chin Med. 2008;10:894–6.
42.
Wang M, Wang Y, Zhao J, Di T, Meng Y, Xie X, Zhai C, Li P. The application of regulating-blood Chinese traditional medicine in treating psoriasis. World Chin Med. 2017;09:2263–8.
43.
Min W, Shupeng S, Yun GA, Yuhua G, Zhong KX. Efficacy of Yinxieling ointment on 675 cases. Chin Tradit Patent Med. 1990;11:21.
44.
Shi Q, Shengshun T, Zhiping S, An ZJ, Yi YJ, Ping L. Clinical study on Huoxuesanyu xiaoyin decoction for treating psoriasis vulgaris with blood stasis syndrome. J Chin Med Mater. 2005;05:442–4.
45.
Wei ZH, Xi ZY. Clinical research on JiaWeiHuangLianJieD decoction for treatment of psoriasis vulgaris. Chin J Inf Tradit Chin Med. 2010;04:65–6.
46.
Baohua Y, Yong X, Guorong S. Clinical research on Tuiyintang combined with NB-UVB for psoriasis vulgaris. LiShizhen Med Mater Med Res. 2014;01:125–7.
47.
Yao D-N, Lu C-J, Wen Z-H, Yan Y-H, Xuan M-L, Li X-Y, Li G, He Z-H, Xie X-L, Deng J-W. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial. Trials. 2016;17(1):140.CrossRefPubMedPubMedCentral
48.
Feng YH, Ning G, Fen TA. The clinical curative effect of dampness Kushen decoction in the treatment of psoriasis vulgaris with damp heat syndrome. Chin J Biochem Pharm. 2017;05:209–10.
49.
Lin YK, Yen HR, Wong WR, Yang SH, Pang JHS. Successful treatment of pediatric psoriasis with Indigo naturalis composite ointment. Pediatr Dermatol. 2006;23(5):507–10.CrossRefPubMed
50.
Zhou N, Bai YP, Man XH, Zhang YB, Kong YH, Ju H, Chang M. Effect of new Pulian Ointment () in treating psoriasis of blood-heat syndrome: a randomized controlled trial. Chin J Integr Med. 2009;15(6):409–14.CrossRefPubMed
51.
Yuqi TT. Review of a treatment for psoriasis using herose, a botanical formula. J Dermatol. 2005;32(12):940–5.CrossRefPubMed
52.
Chen HXJ, Zhang Y. Effects of curcuma on expression of CD45RO, VEGF and iNOS in psoriatic lesions. Chin J Dermato Venerol Integ Trad W Med. 2004;3(4):198–201.
53.
Cho J-W, Lee K-S, Kim C-W. Curcumin attenuates the expression of IL-1β, IL-6, and TNF-α as well as cyclin E in TNF-α-treated HaCaT cells; NF-κB and MAPKs as potential upstream targets. Int J Mol Med. 2007;19(3):469–74.PubMed
54.
Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, Gelfand JM. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. J Am Acad Dermatol. 2008;58(4):625–31.CrossRefPubMedPubMedCentral
55.
Yingbiao T, Zehui C, Qin Y, Limei Y, Hong Z, Min W. Effect of compound curcuma oil cream on psoriasis—like animal model. Pharmacol Clin Chin Mater Med. 2009;03:57–9.
56.
Fuchang L, Jinqi L. Study on prevention and treatment of psoriasis by curcumol ethanol cream and its action mechanism. Pharmacol Clin Chin Mater Med. 2016;03:95–8.
57.
Ali MS, Alam MS, Imam FI, Siddiqui MR. Topical nanoemulsion of turmeric oil for psoriasis: characterization, ex vivo and in vivo assessment. Int J Drug Deliv. 2012;4(2):184.
58.
Sun L, Liu Z, Wang L, Cun D, Tong HH, Yan R, Chen X, Wang R, Zheng Y. Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel. J Control Release. 2017;254:44–54.CrossRefPubMed
59.
Xie X. Effects of Liangxuejiedu formula and indigo on the activation of KC/γδT involved CCL20 in psoriasis model. Master. Beijing University of Chinese Medicine; 2017.
60.
Zhao J, Di T, Wang Y, Wang Y, Liu X, Liang D, Li P. Paeoniflorin inhibits imiquimod-induced psoriasis in mice by regulating Th17 cell response and cytokine secretion. Eur J Pharmacol. 2016;772:131–43.CrossRefPubMed
61.
Di T-T, Ruan Z-T, Zhao J-X, Wang Y, Liu X, Wang Y, Li P. Astilbin inhibits Th17 cell differentiation and ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via Jak3/Stat3 signaling pathway. Int Immunopharmacol. 2016;32:32–8.CrossRefPubMed
62.
Zhao J, Di T, Wang Y, Liu X, Liang D, Zhang G, Li P. Multi-glycoside of Tripterygium wilfordii Hook. f. ameliorates imiquimod-induced skin lesions through a STAT3-dependent mechanism involving the inhibition of Th17-mediated inflammatory responses. Int J Mol Med. 2016;38(3):747–57.CrossRefPubMedPubMedCentral
63.
Wang Y, Zhao J, Zhang L, Di T, Liu X, Lin Y, Zeng Z, Li P. Suppressive effect of β, β-dimethylacryloyl alkannin on activated dendritic cells in an imiquimod-induced psoriasis mouse model. Int J Clin Exp Pathol. 2015;8(6):6665.PubMedPubMedCentral
64.
Wang Y, Zhao J, Di T, Wang M, Ruan Z, Zhang L, Xie X, Meng Y, Lin Y, Liu X. Suppressive effect of β, β-dimethylacryloyl alkannin on activated dendritic cells in psoriasis by the TLR7/8 pathway. Int Immunopharmacol. 2016;40:410–8.CrossRefPubMed
Metadata
Title
Psoriasis therapy by Chinese medicine and modern agents
Authors
Shikang Meng
Zibei Lin
Yan Wang
Zhenping Wang
Ping Li
Ying Zheng
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Chinese Medicine / Issue 1/2018
Electronic ISSN: 1749-8546
DOI
https://doi.org/10.1186/s13020-018-0174-0

Other articles of this Issue 1/2018

Chinese Medicine 1/2018 Go to the issue

Review

Cellular stress response mechanisms of Rhizoma coptidis: a systematic review

Research

Cost-consequence analysis of salvianolate injection for the treatment of coronary heart disease

Review

Seeing the unseen of Chinese herbal medicine processing (Paozhi): advances in new perspectives

Review

Anticancer drug discovery from Chinese medicinal herbs

Research

Characterization and anti-tumor activity of a polysaccharide isolated from Dendrobium officinale grown in the Huoshan County

Research

Wnt5a mediates the effects of Bushen Huoxue decoction on the migration of bone marrow mesenchymal stem cells in vitro